{"id":1020113,"date":"2026-11-11T17:04:27","date_gmt":"2026-11-11T22:04:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/beyond-air-reports-financial-results-and-provides-corporate-update-for-the-quarter-ended-september-30-2026\/"},"modified":"2026-11-11T17:04:27","modified_gmt":"2026-11-11T22:04:27","slug":"beyond-air-reports-financial-results-and-provides-corporate-update-for-the-quarter-ended-september-30-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/beyond-air-reports-financial-results-and-provides-corporate-update-for-the-quarter-ended-september-30-2026\/","title":{"rendered":"Beyond Air Reports Financial Results and Provides Corporate Update for the Quarter Ended September 30, 2026"},"content":{"rendered":"
\n

\n Record quarterly revenue of $2.3 million, representing approximately 28% year-over-year growth, reflecting continued adoption of first-generation LungFit PH<\/em>\n <\/p>\n

\n PMA supplement for second-generation LungFit PH system remains under FDA review; transport capability expected to drive greater market penetration, pending approval<\/em>\n <\/p>\n

\n Reaffirms revenue guidance of $8 million for CY2026 and $16\u2013$18 million for CY2027<\/em>\n <\/p>\n

\n Conference call today at 4:30 p.m. ET <\/em>\n <\/p>\n

GARDEN CITY, N.Y., Nov. 11, 2026 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients\u2019 lives, today announced financial results for the quarter ended September 30, 2026, and provided a corporate update.<\/p>\n

\u201cBuilding on the commercial momentum we are generating with our first-generation LungFit PH system, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth, pending FDA approval,\u201d said Robert Goodman, Chief Executive Officer of Beyond Air. \u201cOur US pipeline is now experiencing unprecedented expansion with an acceleration in demand for our first-generation system and high receptivity to our technology and its operational efficiencies, creating a natural demand for our next generation product. We are especially pleased with the pace of new account wins and rate of renewals, which speak to the high level of customer satisfaction with our unique technology \u2013 all of which we believe we can leverage into the potential future launch of our second-generation LungFit PH system. Subject to FDA approval, the system is designed to provide a smaller footprint, reduced weight, simplified operation, longer service intervals and expanded operational flexibility. The PMA supplement seeks expanded FDA labeling that would permit use during patient transport by air and ground.\u201d<\/p>\n

Mr. Goodman continued, \u201cWe remain encouraged by our active and productive discussions with the FDA and the progress we are making toward completing the remaining steps in the review process for the second-generation LungFit PH system. We expect to complete our audit-readiness process in mid-December, and subject to FDA inspections and final approval thereafter.\u201d<\/p>\n

\n Recent Financial and Operating Highlights<\/strong>\n <\/p>\n